What will bring all back to work! Joe Biden is clueless... Keeping the eyes on the prize! POTUS Capricor, CAPR yesterday, beat on all numbers and has brought a VLP Vaccine into the long-term solutions FDA TRIALS CAP-1002. talkmarkets.com/.../blockbuster-sar-cov2-disrupters-pre-icu--admitted-icu-patient-treatments--covid-19-t-cell-vaccine-horizon PT $14 - $24 3-12 month outlook.

Keeping the eyes on the prize:

Good connecting article for why the PT had hit the 52 weeks high $12.32 and maybe the reason for the August 6th or 8th earnings report in jacking the share price towards becoming a true M&A candidate or given the blessings of the FDA's approval for CAP-1002 BLA filing for uses.

READ:

talkmarkets.com/.../blockbuster-sar-cov2-disrupters-pre-icu--admitted-icu-patient-treatments--covid-19-t-cell-vaccine-horizon

READ:

endpts.com/microcap-capricor-soars-on-interim-phii-dmd-data-showing-functional-benefit-for-older-patients/

Good connecting article for why the PT had hit the 52 weeks high $12.32 and maybe the reason for the August 6th or 8th earnings report in jacking the share price towards becoming a true M&A candidate or given the blessings of the FDA's approval for CAP-1002 BLA filing for uses.

READ:

endpts.com/microcap-capricor-soars-on-interim-phii-dmd-data-showing-functional-benefit-for-older-patients/

Very Important *****FYI for those seeking the best and earliest buy for both MESO with their BLA pending FDA approval on Remestence-L and CAPR CAP-1002 are just a few we are closely watching.

READ:

bioinformant.com/capricor-developing-treatment-dmd/ Inivio INO just got their BLA approval for their HPV suite of critical advancements in helping those stricken with Throat complications of HPV and that in critically advancing their VGX-3100 towards getting FDA final approvals.

Capricor CAPR has a few irons in the fire coming up when they present their upcoming second-quarter earnings and corporation pipeline status.

READ:

talkmarkets.com/.../blockbuster-sar-cov2-disrupters-pre-icu--admitted-icu-patient-treatments--covid-19-t-cell-vaccine-horizon

The first big iron for CAPR comes with a pending BLA for getting or meeting Orphan Drug Approval Status for their CAP-1002 for male boys and younger adult males with Duchenne muscular dystrophy (DMD) in 7 Major Markets.

This Iron is also quite remarkable with the incredible successes from the uses of MSCs and Exosome biotechnology advancements and the repurposing of their most current pipeline candidates awaiting approvals from the FDA for the accepted treatment protocols COVID-19 SARSCoV2; the eventual Orphan Drug Status for both Capricor CAPR CAP-1002 and Mesoblast LTD MESO for their Remestence-L.

Again, both MESO and CAPR for battling and achieving a true Disrupter Status in this war against China's born novel Coronavirus affecting our entire plant, since possibly October of 2019, when China kept this secret biological weapon hidden from the rest of the entire living masses around our world economies.

Keep up with the currently approved study for CAPR below as a link is provided. ClinicalTrials.gov identifier (NCT number): NCT04338347

READ:

https://clinicaltrials.gov/ct2w/NCT04338347

Very Important *****FYI for those seeking the best and earliest buy for both MESO with their BLA pending FDA approval on Remestence-L and CAPR CAP-1002 are just a few we are closely watching. READ: bioinformant.com/capricor-developing-treatment-dmd/ Inivio INO just got their BLA approval for their HPV suite of critical advancements in helping those stricken with Throat complications of HPV and that in critically advancing their VGX-3100 towards getting FDA final approvals. Capricor CAPR has a few irons in the fire coming up when they present their upcoming second-quarter earnings and corporation pipeline status. READ: talkmarkets.com/.../blockbuster-sar-cov2-disrupters-pre-icu--admitted-icu-patient-treatments--covid-19-t-cell-vaccine-horizon The first big iron for CAPR comes with a pending BLA for getting or meeting Orphan Drug Approval Status for their CAP-1002 for male boys and younger adult males with Duchenne muscular dystrophy (DMD) in 7 Major Markets. This Iron is also quite remarkable with the incredible successes from the uses of MSCs and Exosome biotechnology advancements and the repurposing of their most current pipeline candidates awaiting approvals from the FDA for the accepted treatment protocols COVID-19 SARSCoV2; the eventual Orphan Drug Status for both Capricor CAPR CAP-1002 and Mesoblast LTD MESO for their Remestence-L. Again, both MESO and CAPR for battling and achieving a true Disrupter Status in this war against China's born novel Coronavirus affecting our entire plant, since possibly October of 2019, when China kept this secret biological weapon hidden from the rest of the entire living masses around our world economies. Keep up with the currently approved study for CAPR below as a link is provided. ClinicalTrials.gov identifier (NCT number): NCT04338347 READ: https://clinicaltrials.gov/ct2/shoVery Important *****FYI for those seeking the best and earliest buy for both MESO with their BLA pending FDA approval on Remestence-L and CAPR CAP-1002 are just a few we are closely watching. READ: bioinformant.com/capricor-developing-treatment-dmd/ Inivio INO just got their BLA approval for their HPV suite of critical advancements in helping those stricken with Throat complications of HPV and that in critically advancing their VGX-3100 towards getting FDA final approvals. Capricor CAPR has a few irons in the fire coming up when they present their upcoming second-quarter earnings and corporation pipeline status. READ: talkmarkets.com/.../blockbuster-sar-cov2-disrupters-pre-icu--admitted-icu-patient-treatments--covid-19-t-cell-vaccine-horizon The first big iron for CAPR comes with a pending BLA for getting or meeting Orphan Drug Approval Status for their CAP-1002 for male boys and younger adult males with Duchenne muscular dystrophy (DMD) in 7 Major Markets. This Iron is also quite remarkable with the incredible successes from the uses of MSCs and Exosome biotechnology advancements and the repurposing of their most current pipeline candidates awaiting approvals from the FDA for the accepted treatment protocols COVID-19 SARSCoV2; the eventual Orphan Drug Status for both Capricor CAPR CAP-1002 and Mesoblast LTD MESO for their Remestence-L. Again, both MESO and CAPR for battling and achieving a true Disrupter Status in this war against China's born novel Coronavirus affecting our entire plant, since possibly October of 2019, when China kept this secret biological weapon hidden from the rest of the entire living masses around our world economies. Keep up with the currently approved study for CAPR below as a link is provided. ClinicalTrials.gov identifier (NCT number): NCT04338347 READ: https://clinicaltrials.gov/ct2w/NCT04338347

Very Important *****FYI for those seeking the best and earliest buy for both MESO with their BLA pending FDA approval on Remestence-L and CAPR CAP-1002 are just a few we are closely watching. READ: bioinformant.com/capricor-developing-treatment-dmd/ Inivio INO just got their BLA approval for their HPV suite of critical advancements in helping those stricken with Throat complications of HPV and that in critically advancing their VGX-3100 towards getting FDA final approvals. Capricor CAPR has a few irons in the fire coming up when they present their upcoming second-quarter earnings and corporation pipeline status. READ: talkmarkets.com/.../blockbuster-sar-cov2-disrupters-pre-icu--admitted-icu-patient-treatments--covid-19-t-cell-vaccine-horizon The first big iron for CAPR comes with a pending BLA for getting or meeting Orphan Drug Approval Status for their CAP-1002 for male boys and younger adult males with Duchenne muscular dystrophy (DMD) in 7 Major Markets. This Iron is also quite remarkable with the incredible successes from the uses of MSCs and Exosome biotechnology advancements and the repurposing of their most current pipeline candidates awaiting approvals from the FDA for the accepted treatment protocols COVID-19 SARSCoV2; the eventual Orphan Drug Status for both Capricor CAPR CAP-1002 and Mesoblast LTD MESO for their Remestence-L. Again, both MESO and CAPR for battling and achieving a true Disrupter Status in this war against China's born novel Coronavirus affecting our entire plant, since possibly October of 2019, when China kept this secret biological weapon hidden from the rest of the entire living masses around our world economies. Keep up with the currently approved study for CAPR below as a link is provided. ClinicalTrials.gov identifier (NCT number): NCT04338347 READ: https://clinicaltrials.gov/ct2/show/NCT04338347

I agree, the title of the article was a mouthful! I had a hard time shorting it, mostly due to the sure nature of covering a myriad of treatments and vaccines for ongoing war.

I will use my reply this morning, in taking efforts on getting out my frustrations for a NOVEL CORONAVIRUS that has killed hundreds of thousands, and yet has not met it's match to date.

Yes, I said WAR--being waged upon China's Deadly Gift--sent around the world with a Kiss...

China's well documented "Evil Intents" by the very nature of evil, as driven China determination in becoming the one and only superpower over our free democracies we all seemingly hold so dear.

I say this, because, it seems our LEFT-WING MEDIA and the Tech-Valley of Google's, Amazon's, Apple's, Twitter's, and a host of Democratic DNC elected Governor's, Mayor's, and elected officials throughout the many states and cities; seeing out and out rioting, causing untold damages throughout our United States.

Just getting out my frustrations this morning. I just can't believe the lengths the LEFT-WING Media has taken in trying to effect a presidential election in 2020.

We can all agree, when one can stand behind the cause of when an African American, who had been suffocated with a lethally used choke hold--as the one loan officer wouldn't release pressure--as many were yelling at the other two law enforcement officers to stop George's death as he was killed in Minneapolis, Minnesota, George Floyd's death, at the hands then, three identified law enforcement officers, with one actually being the stone blooded killer.

NO ONE can disagree with the outrage in the senseless killing of George Floyd, in wear legal protest is quite a correct response.

We in NO WAY or in ANY SHAPE, CONDONE what has gone on behind those that lead BLM condoning the extremes of lawlessness, an increase in civilian death's along with those wearing the BLUE as the violence seen over these past several months And within their past history's.

NO ONE should stand-by and allow lawlessness and outright Anarchies, as being played out in Portland, Seattle, Chicago, and other televised news coming out from a trusted NEWS SOURCE of FOX News; as I recommend many to turn towards, if they want the truth and not the FAKE NEWS Agendas.

Yes, FAKE NEWS AGENDAS being waged against our own 1st amendment rights, and though, I do find some other news outlets not afraid in getting out the truth behind all these very Evil and Diabolical efforts being played out right before all of our very eyes.

God bless! Thank you : -)

The following link should be kept close at hand when dealing with COVID-19 concerns and timely SARS-CoV2 ICU Patient Treatment Protocols: www.ashp.org/.../ASHP-COVID-19-Evidence-Table.ashx Viewing the Thoracic Concerns: www.atsjournals.org/.../rccm.201908-1581ST

The coronavirus disease of the 2019 pandemic caused by the SARS-CoV-2 virus continues to inflict significant morbidity and mortality around the globe. A variety of cardiovascular presentations of SARS-CoV-2 infection have been described so far. However, the impact of SARS-CoV-2 on the right ventricle is largely unknown. Due to its pathophysiologic relevance, the right ventricle finds itself in the eye of the storm of coronavirus disease of 2019, placing it at a higher risk of failure. Increased afterload from acute respiratory distress syndrome and pulmonary embolism, negative inotropic effects of cytokines, and direct angiotensin-converting enzyme 2-mediated cardiac injury from SARS-CoV-2 are potential mechanisms of right ventricle dysfunction in coronavirus disease of 2019. Early detection and treatment of right ventricle dysfunction may lead to decreased mortality and improved patient outcomes in coronavirus disease of 2019. MOBIL COVID-19 PROTOCOLS: https://mobile.health.mil/asp/#/covid-19